Molecular structure of enalaprilatMolecular structure of enalaprilat
Find information on thousands of medical conditions and prescription drugs.

Enalapril

Enalapril is an angiotensin converting enzyme (ACE) inhibitor used in the treatment of hypertension and some types of chronic heart failure. Enalapril was the first member of the group of ACE inhibitors known as the dicarboxylate-containing ACE inhibitors. It is marketed by Merck & Co. (Merck, Sharp & Dohme) under the trade names, RenitecĀ® and VasotecĀ®. more...

Home
Diseases
Medicines
A
B
C
D
E
E-Base
Ecstasy (drug)
Edecrin
Edrophonium
Edrophonium chloride
Efavirenz
Effexor
Eflornithine
Elavil
Eldepryl
Elidel
Eligard
Elitek
Elixomin
Elixophyllin
Ellagic acid
Elmiron
Eloxatin
Elspar
Emtriva
Emylcamate
Enalapril
Enalaprilat
Enalaprilat
Endep
Enflurane
Enoxaparin sodium
Entacapone
Enulose
Epi-pen
Epinephrine
Epirubicin
Epitol
Epivir
Epogen
Eprosartan
Ergocalciferol
Ergoloid Mesylates
Ergotamine
Eryc
Eryped
Erythromycin
Esgic
Eskalith
Esmolol
Estazolam
Estazolam
Estrace
Estraderm
Estradiol
Estradiol
Estradiol valerate
Estring
Estrogel
Estrone
Estrostep
Ethacridine
Ethambutol
Ethchlorvynol
Ethosuximide
Ethotoin
Etiracetam
Etodolac
Etopophos
Etoposide
Etorphine
Evista
Exelon
Exemestane
Hexal Australia
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Development

Enalapril was developed by researchers at Merck & Co. as part of their efforts to develop novel treatments for hypertension by modulating the renin-angiotensin-aldosterone (RAS) system.

The success of Squibb in developing the first inhibitor, captopril, provided a major impetus for Merck's research laboratories to develop a competing product. Captopril was not without its problems, however, as it was believed (and shown to be true) that the sulfhydryl-moeity of captoril was responsible for such adverse effects as metallic taste.

Enalaprilat

Enalaprilat, the first dicarboxylate-containing ACE inhibitor, was developed partly to overcome these limitations of captopril. The sulfhydryl-moeity was replaced by a carboxylate-moeity, but additional modifications were required in its structure-based design to achieve a similar potency to captopril.

Enalaprilat itself, however, was not without its problems. The consequence of the structural modifications was that it proved to be have unfavourable ionisation characteristics to allow sufficient potency for oral administration (in tablets). Thus enalaprilat was only suitable for intravenous administration. This was overcome by the researchers at Merck by the esterification of enalaprilat with ethanol to produce enalapril. As a prodrug, enalapril is metabolised in vivo to the active form enalaprilat by various esterases.

A prototype for others

Most importantly, perhaps, the QSAR-based modifications in structure serendipitously led to an improved understanding of the structure of ACE which aided in the development of subsequent carboxylate-containing ACE inhibitors.

Read more at Wikipedia.org


[List your site here Free!]


Faulding To Market Enalaprilat Injection/Enalapril Tablets
From Worldwide Biotech, 10/1/00

International pharmaceutical and health care company, F H Faulding & Co Limited (Faulding), Adelaide, South Australia, has announced that its Faulding Pharmaceuticals division has received final approval from the Food and Drug Administration (FDA) in the United States for its abbreviated new drug application (ANDA) for enalaprilat injection, following the expiry of the paediatric exclusivity period on 22 August 2000. Enalaprilat injection is a generic version of Vasotec(R), which is indicated for treatment of hypertension and is marketed by Merck & Co. Total brand sales in 1999 for Vasotec(R) I.V. were approximately US$41 million.

Faulding Pharmaceuticals will also launch enalapril maleate tablets 2.5mg, 5mg, 10mg and 20mg under the Purepac brand in the United States, having obtained distribution and marketing rights from Ranbaxy, an Indian pharmaceutical company. Ranbaxy received final FDA approval for their ANDAs for enalapril tablets on 22 August 2000. Enalapril maleate tablets are a generic version of Vasotec(R) in its oral form, which is also indicated for treatment of hypertension and marketed by Merck & Co. Total brand sales in 1999 for the oral version of Vasotec(R) were approximately US$690 million.

Commercial distribution of both enalaprilat injection and enalapril maleate tablets will commence immediately.

Frank Condella, president and CEO of Faulding Pharmaceuticals, said "Faulding Pharmaceuticals has a strong pipeline of products to ensure good growth. We are also pursuing innovative means of augmenting that pipeline through marketing arrangements with other pharmaceutical companies who can benefit from our distribution network and established customer relationships."

"The launch of enalaprilat injection is a good example of the strength of our internal development and regulatory ability with Faulding receiving tentative approval from the FDA in less than 12 months when the average approval time is 20 months. The launch of enalapril maleate tablets demonstrates our ability to expand our range of products in other ways. We believe that Faulding is unique in its offering of both the I.V. and oral forms of this product."

Faulding Pharmaceuticals currently has 14 products awaiting approval with the FDA.

Faulding is a worldwide health and personal care company, listed on the Australian Stock Exchange. Faulding's principal businesses are generic oral and injectable pharmaceuticals, consumer health products, the provision of distribution and retail management services to pharmacies and logistics management services to hospitals. Faulding's products are sold in over 70 countries.

For more information, call +61 8 8205 6500.

COPYRIGHT 2000 Worldwide Videotex
COPYRIGHT 2000 Gale Group

Return to Enalapril
Home Contact Resources Exchange Links ebay